Mitoxantrone with Intermediate-or High-Dose Ara-C for Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

E. Morra Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

M. Lazzarino Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

A. Corso Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

E. Brusamolino Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

G. Pagnucco Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

C. Castagnola Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

P. Bernasconi Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

A. Santagostino Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

A. Livraghi Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

C. Bernasconi Chair of Hematology, University of Pavia; Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy

show all

References

Hiddemann W., Kreutzmann H., Straif K., et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukaemia. Blood 1987; 69: 744–749
PubMed Web of Science ®Google Scholar
Kantarjian H., Walters R., Keating M., et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 1990; 65: 5–8
PubMed Web of Science ®Google Scholar
Ho A., Del Valle F., Ruckle H., et al. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 1989; 64: 1388–1392
PubMed Web of Science ®Google Scholar
Morra E., Lazzarino M., Inverardi D., et al. Systemic high dose Ara-C for the treatment of meningeal leukemia in acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J. Clin Oncol 1986; 4: 1207–1211
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Mitoxantrone with Intermediate-or High-Dose Ara-C for Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mitoxantrone with Intermediate-or High-Dose Ara-C for Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date